Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: M. Ramle who wrote (1161)	9/15/1998 1:41:00 PM
From: David Howe	Read Replies (2) of 10280

Yes. The CEO of SEPR will be on CNBC tomorrow (probably before the market opens). The interview should be interesting. They rarely give the guest enough time and they rarely ask relevant questions. Regarding my earlier posts. I made at least two mistakes. The market for Levalbuteral's parent drug is $1.4 billion, however the market for Levalbuteral as a nebule is around $200 million. Also, I believe that SEPR is close to filing an NDA on (R)-fluoxetine, not (S)-fluoxetine. I had them reversed. (R)-fluoxetine has a much larger market than (S)-fluoxetine (prozac-migraine). Dave

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next